Core Laboratories
CLB
191 hedge funds and large institutions have $946M invested in Core Laboratories in 2024 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 74 reducing their positions, and 28 closing their positions.
391% more call options, than puts
Call options by funds: $2.69M | Put options by funds: $548K
0% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 28
1.36% less ownership
Funds ownership: 110.17% → 108.81% (-1.4%)
2% less funds holding
Funds holding: 194 → 191 (-3)
10% less capital invested
Capital invested by funds: $1.05B → $946M (-$102M)
18% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 74
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
CLB Hedge Fund Activity: Q3 2024 in Review
191 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Core Laboratories (CLB) for Q3 2024, worth a combined $946M — down 9.7% from $1.05B a quarter earlier.
Fund positioning in CLB was balanced in Q3 2024: 28 funds opened new positions, 28 closed out, 61 added to existing stakes and 74 trimmed.
The largest buyer was Disciplined Growth Investors, adding an estimated $24M. The largest seller was Congress Asset Management, exiting entirely with an estimated $34.2M sold.
- 191 institutional investors held Core Laboratories (CLB) as of Q3 2024, down from 194 in Q2 2024.
- Funds reported $946M of Core Laboratories stock for Q3 2024, down 9.7% quarter-over-quarter.
- 28 funds opened new Core Laboratories positions in Q3 2024 and 28 closed out, a net change of 0 holders.
- The largest Core Laboratories buyer in Q3 2024 was Disciplined Growth Investors, an estimated $24M added.
- The largest Core Laboratories seller in Q3 2024 was Congress Asset Management, an estimated $34.2M sold.
Based on aggregated 13F filings for Q3 2024.